Abolis key facts
- Developer of a microbial biotechnology platform designed to change production models of high-value molecules.
- Abolis’s last known valuation is $53.1M.
- It has raised $40.1M; the latest was Later Stage VC ($38.8M) in Sep 2024.
- Notable investors include Evonik Venture Capital, BOLD (Business Opportunities for L'Oréal Development), Clay Capital (Singapore), DeepTech & Climate Fonds, Genopole — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch Abolis: the Monday email on marks, rounds and moves
Abolis funding rounds
No funding rounds for Abolis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Abolis valuation
Abolis's last known valuation is $53.1 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Abolis investors
10 investors are on record for Abolis, including Evonik Venture Capital, BOLD (Business Opportunities for L'Oréal Development), Clay Capital (Singapore) and DeepTech & Climate Fonds.
About Abolis
Developer of a microbial biotechnology platform designed to change production models of high-value molecules. The company offers advanced genetic tools, ML-driven pathway optimization, and scalable bioprocesses, enabling pharmaceutical and industrial manufacturers, cost-effective and sustainable production of complex molecules.
- Sector
- Healthcare
- HQ
- Paris, France
- Employees
- 84
- Website
- abolis.fr/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Abolis’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.